ArticleAdvanced biotechnology2026
SPAID: a comprehensive database for disease-specific autoantigens in autoimmune disorders.
Article in Advanced biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Autoimmune diseases (ADs) are chronic inflammatory disorders characterized by complex etiologies and significant diagnostic challenges. Although autoantigens are critical for precision diagnosis and therapy, much of the immunogenic landscape remains unexplored due to the historical focus on canonical proteins. Here, we developed SPAID ( https://spaid.renlab.cn ), a comprehensive resource for candidate autoantigen discovery across 14 ADs that integrates canonical and non-canonical proteins within a two-level evidence framework. The validated level contains proteins associated with experimentally confirmed epitopes from T-cell assays and major histocompatibility complex (MHC) ligand assays. The proteomics-based level contains proteins identified by mass spectrometry (MS) from human samples, further annotated with differential expression patterns, immunogenicity scores, and functional features to support candidate autoantigen discovery and further validation. By combining validated evidence with proteomics-based evidence, SPAID enables the comprehensive characterization of candidate autoantigen repertoires and facilitates mechanistic investigation into antigen origins and pathogenic recognition. Overall, SPAID provides a foundational resource for advancing antigen-centered research and developing novel diagnostic and therapeutic strategies in autoimmunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.